PHARMABCINE INC Mediaroom - PR Newswire APAC

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

* Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC...

2024-10-15 09:51 1261

PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

* Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of...

2024-07-02 11:02 2177

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024

* Presentation at ARVO 2024 gained attention as Eylea (aflibercept) eye drops demonstrated simila...

2024-05-23 08:51 1605

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

* Preclinical data from the next generation eyedrop platform to be unveiled for the first time at...

2024-04-23 07:25 1820

PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors

* Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309...

2024-01-24 10:01 1320

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

* Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (IS...

2023-11-23 10:31 1652

PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

* Safety Review Committee evaluated dose level 1 safety data of PMC-403 and approved advancing to...

2023-11-09 21:00 1520

PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

DAEJEON, South Korea, July 26, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical...

2023-07-26 20:00 1685

PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

DAEJEON, South Korea, May 23, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-...

2023-05-23 20:00 1780

PharmAbcine to participate in "BIO International Convention 2023"

DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-s...

2023-05-08 20:00 2216

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical...

2022-12-12 21:00 1922

PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week

DAEJEON, South Korea, Dec. 8, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-...

2022-12-08 21:00 1719

Latest News

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024

PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

PharmAbcine to participate in "BIO International Convention 2023"

PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)

PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week

PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

PharmAbcine to Participate in BIO-Europe 2022

PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention

PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study

PharmAbcine Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022

RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics

NuclixBio Announces a Collaborative Research Agreement with PharmAbcine